Gemcitabine and Cisplatin With/Without Anlotinib in Advanced Nasopharyngeal Carcinoma
Status:
Unknown status
Trial end date:
2021-07-30
Target enrollment:
Participant gender:
Summary
This is a Phase III randomized controlled multi-center trial comparing anlotinib plus
Gemcitabine/Cisplatin with placebo plus Gemcitabine/Cisplatin in previous untreated patients
with recurrent/metastatic Nasopharyngeal Carcinoma, in order to verify the efficacy and
security of anlotinib in mNPC patients.
Phase:
Phase 3
Details
Lead Sponsor:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd